We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems.
Advanced to the highest dose level in the Phase 1 dose-escalation clinical study of BDC-3042 in patients with advanced cancersPresented updated preclinical activity of BDC-4182 and key learnings...
BDC-4182 demonstrated compelling anti-tumor activity and an acceptable safety profile in preclinical studies BDC-4182 outperformed cytotoxic claudin 18.2 ADCs in syngeneic model Learnings from...
REDWOOD CITY, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of...
REDWOOD CITY, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.09 | 17.6470588235 | 0.51 | 0.6 | 0.496 | 278904 | 0.55203462 | CS |
4 | 0.014 | 2.38907849829 | 0.586 | 0.606299 | 0.475 | 215408 | 0.53525516 | CS |
12 | -0.04 | -6.25 | 0.64 | 0.718 | 0.475 | 157169 | 0.58487115 | CS |
26 | -0.1326 | -18.0999180999 | 0.7326 | 0.78 | 0.475 | 162084 | 0.64039292 | CS |
52 | -0.54 | -47.3684210526 | 1.14 | 1.56 | 0.475 | 168346 | 0.82325385 | CS |
156 | -4.27 | -87.6796714579 | 4.87 | 4.99 | 0.475 | 189097 | 1.52924523 | CS |
260 | -21.39 | -97.2714870396 | 21.99 | 43.07 | 0.475 | 192012 | 6.52816703 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions